Silverman SL, Watts NB, Delmas PD et al (2007) Effectiveness of b

Silverman SL, Watts NB, Delmas PD et al (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of Olaparib ic50 therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int

18:25–34CrossRefPubMed 21. Cadarette SM, Katz JN, Brookhart MA et al (2008) Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637–646PubMed 22. Curtis JR, Westfall AO, Cheng H et al (2009) RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 20(6):973–978CrossRefPubMed 23. Harris ST, Reginster JY, Harley C et al (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44(5):758–765CrossRefPubMed 24. Mauri L, Silbaugh TS, Garg P et al (2008) Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359:1330–1342CrossRefPubMed find more 25. Jackson LA, Jackson ML, Nelson JC et al (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35:337–344CrossRefPubMed 26. Bonnick S, Saag KG, Kiel DP et al (2006) Comparison of weekly treatment of postmenopausal

osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631–2637CrossRefPubMed 27. Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.

Calcif Tissue Int 74:129–135CrossRefPubMed 28. Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124CrossRefPubMed for 29. Melton LJ 3rd, Thamer M, Ray NF et al (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23CrossRefPubMed 30. American College Of Rheumatology Ad Hoc Committee On Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503CrossRef 31. Riggs BL, Melton LJ 3rd, Robb RA et al (2006) Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. J Bone Miner Res 21:315–323CrossRefPubMed 32. Johnell O, Kanis JA, Odén A et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179CrossRefPubMed 33. Brookhart MA, Avorn J, Katz JN et al (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251–256CrossRefPubMed 34.

Comments are closed.